Streamlining processes like trial site selection and FDA documentation can make a meaningful difference in development ...

The collaboration will improve inspection, verification, serialization and labeling processes to drive greater efficiency and ...

Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei ...

As AI becomes more prevalent, organizations need to leverage the power of scope, scale, speed, and human-AI collaboration for ...

NTU Singapore is introducing two new undergraduate degree programmes in robotics and advanced chemical and pharmaceutical manufacturing in August ...

Nxera Pharma, previously known as Sosei Heptares or the Sosei Group, has entered a collaboration and licensing agreement with Antiverse to design antibodies for G-protein coupled receptors (GPCRs).

FMI’s latest analysis underscores a remarkable surge in demand for pharmaceutical products within the Kingdom, with market value expected to exceed USD 10,113.1 million by 2024. This impressive growth ...

The pharmaceutical industry is experiencing a fundamental transformation. AI and computational approaches are no longer optional tools. They have become essential drivers of innovation across the ...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning ... future ...

Nxera Pharma & Antiverse collaborate to design novel GPCR-targeted antibody therapeutics using generative AI: Tokyo, Japan Wednesday, November 6, 2024, 13:00 Hrs [IST] Nxera Pharm ...

Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera ... s generative AI antibody design expertise, including its proprietary machine-learning-generated ...